As many as 5.3 million Americans are currently living with Alzheimer's disease. Today there is no cure, no disease-modifying treatment, and no way to prevent the disease.

ADNI II aims to build on the success of ADNI, which concluded in 2010. ADNI study investigators have submitted a grant renewal application to the NIH to continue the ADNI study for an additional five years (From late 2010 to late 2015). Through a partnership between the National Institute on Aging and the private sector, ADNI II will continue to track the current ADNI subjects and enroll additional normal, mildly cognitively impaired, and Alzheimer's disease patients, as well as people with early or very mild cognitive impairment. Additional plans for ADNI II include PET imaging scans on every new patient enrolled.

ADNI2 Partners

Alzheimer’s Association
Alzheimer’s Drug Discovery Foundation
Amorfix Life Sciences
BioClinica
Biogen Idec
Bristol-Myers Squibb
Canadian Institutes of Health Research
Eisai, Inc.
Elan Pharmaceuticals
Eli Lilly and Company
Roche
GE Healthcare
Genentech
Innogenetics
IXICO
Janssen Alzheimer Immunotherapy
Johnson & Johnson
Medpace
Merck
Meso Scale Diagnostics
NeuroRx
Novartis Pharmaceuticals
Pfizer, Inc.
Piramal Imaging
Servier
Synarc
Takeda

Get involved. Partner with us.

To learn more about partnership opportunities with the ADNI II project, contact us:

Julie Wolf-Rodda, Director of Partnership Development
Phone: (301) 402-5311
E-mail: jwolf-rodda [at] fnih [dot] org